VaxInnate’s Technology Platform is based on Toll-like Receptor (TLR) technology, which dramatically improves vaccine immunogenicity and efficacy.
The VaxInnate Technology Platform is radically different. It’s scalable. It’s less expensive to manufacture. It’s faster to produce. Compared to traditional egg-based vaccine production, which can take as long 5 to 6 months to produce a first dose, our technology platform can deliver first doses within the first 12 weeks.
VaxInnate’s proprietary Toll-like Receptor (TLR) technology genetically fuses vaccine antigens to the bacterial protein flagellin. This triggers an immune response in the innate immune system. Using recombinant DNA techniques we are able to produce unlimited quantities of vaccine in extremely rapid timeframes, with very low infrastructure costs.